Next-generation treatment options for patients with hard-to-treat tumors

Our partner Erasmus MC has recently obtained approval from the Dutch regulatory authorities to run a first Phase I clinical trial with MAGE-C2/HLA-A2 TCR and epigenetic drugs to treat melanoma and head-and-neck carcinoma. This trial represents a lead example resulting from Pan Cancer T’s platforms, and includes a dose-escalation of TCR T cells and aims at recruiting up to 12 patients and demonstrating the maximum tolerated dose.

Pan Cancer T implements Erasmus MC’s validated discovery and screening platforms, and will jump-start new Phase I trials along the same principles of safety and efficacy with the below-listed lead PCT products.